1. Home
  2. ICCC vs SRZN Comparison

ICCC vs SRZN Comparison

Compare ICCC & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICCC
  • SRZN
  • Stock Information
  • Founded
  • ICCC 1982
  • SRZN 2015
  • Country
  • ICCC United States
  • SRZN United States
  • Employees
  • ICCC N/A
  • SRZN N/A
  • Industry
  • ICCC Biotechnology: Pharmaceutical Preparations
  • SRZN Medicinal Chemicals and Botanical Products
  • Sector
  • ICCC Health Care
  • SRZN Health Care
  • Exchange
  • ICCC Nasdaq
  • SRZN Nasdaq
  • Market Cap
  • ICCC 35.4M
  • SRZN 31.3M
  • IPO Year
  • ICCC 1987
  • SRZN N/A
  • Fundamental
  • Price
  • ICCC $4.29
  • SRZN $9.30
  • Analyst Decision
  • ICCC
  • SRZN
  • Analyst Count
  • ICCC 0
  • SRZN 0
  • Target Price
  • ICCC N/A
  • SRZN N/A
  • AVG Volume (30 Days)
  • ICCC 6.8K
  • SRZN 8.5K
  • Earning Date
  • ICCC 08-08-2024
  • SRZN 08-07-2024
  • Dividend Yield
  • ICCC N/A
  • SRZN N/A
  • EPS Growth
  • ICCC N/A
  • SRZN N/A
  • EPS
  • ICCC N/A
  • SRZN N/A
  • Revenue
  • ICCC $21,282,719.00
  • SRZN N/A
  • Revenue This Year
  • ICCC N/A
  • SRZN N/A
  • Revenue Next Year
  • ICCC N/A
  • SRZN N/A
  • P/E Ratio
  • ICCC N/A
  • SRZN N/A
  • Revenue Growth
  • ICCC 32.89
  • SRZN N/A
  • 52 Week Low
  • ICCC $4.05
  • SRZN $4.50
  • 52 Week High
  • ICCC $5.87
  • SRZN $16.19
  • Technical
  • Relative Strength Index (RSI)
  • ICCC 46.74
  • SRZN 42.04
  • Support Level
  • ICCC $4.10
  • SRZN $8.85
  • Resistance Level
  • ICCC $4.56
  • SRZN $10.24
  • Average True Range (ATR)
  • ICCC 0.14
  • SRZN 0.89
  • MACD
  • ICCC 0.01
  • SRZN -0.11
  • Stochastic Oscillator
  • ICCC 25.33
  • SRZN 20.93

About ICCC ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

About SRZN Surrozen Inc.

Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).

Share on Social Networks: